
MiniMed picks up CE mark for MiniMed 780G pump with Instinct sensor made by Abbott
MiniMed (Nasdaq:MMED) announced that it received CE mark for the use of its MiniMed 780G with the Instinct sensor made by Abbott.

MiniMed (Nasdaq:MMED) announced that it received CE mark for the use of its MiniMed 780G with the Instinct sensor made by Abbott.

Matthew Jones is using experimental technology and computation to decode the molecular processes that underlie the way tumors evolve to resist treatment by pinpointing how and when aggressive mutations arise.

Leveraging the potential of NfL as a biomarker, researchers from Japan have developed the world’s first aptamer (tiny, single-stranded synthetic DNA molecules) that can bind NfL with high affinity and specificity

Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have found that depleting a clotting protein made by the liver could slow down pancreatic cancer.

Boron agents termed GluBs, developed by Science Tokyo researchers, have overcome a key limitation in cancer therapy by entering tumor cells through a pathway that standard drugs cannot use.

Now, researchers from the Tissue Engineering Group of the Department of Histology at the University of Granada’s Faculty of Medicine and the ibs.GRANADA Institute for Biomedical Research have created highly biocompatible, resistant, and transparent corneal implants from scales of various types of fish commonly found on the market, such as carp. The findings are published in the journal Materials & Design.

Cancer cells consume oxygen and nutrients at a higher rate than healthy tissue,. This drug delivery system senses those physical changes and guides medicine to the disease. The drug is released only when it encounters those tumor-specific conditions.

A new study led by researchers from VIB and KU Leuven shows that immune cells called microglia can actively promote the formation of plaques in Alzheimer’s disease.

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel Deaconess Medical Center.

In a significant advancement for lab-on-chip technology, IBEC researchers in the frame of the European project BLOC, have demonstrated the first integration of a benchtop nuclear magnetic resonance (NMR) spectrometer with a microfluidic cell culture platform capable of real-time metabolic monitoring,